Document is current
Any future updates will be listed below
-
Authors
Holderfield, Matthew
Lee, Bianca J.
Jiang, Jingjing
Tomlinson, Aidan
Seamon, Kyle J.
Mira, Alessia
Patrucco, Enrico
Goodhart, Grace https://orcid.org/0009-0004-8549-8852
Dilly, Julien https://orcid.org/0000-0002-4006-5285
Gindin, Yevgeniy
Dinglasan, Nuntana
Wang, Yingyun
Lai, Lick Pui
Cai, Shurui
Jiang, Lingyan
Nasholm, Nicole https://orcid.org/0000-0002-5451-4985
Shifrin, Nataliya
Blaj, Cristina
Shah, Harshit
Evans, James W.
Montazer, Nilufar
Lai, Oliver
Shi, Jade
Ahler, Ethan
Quintana, Elsa
Chang, Stephanie
Salvador, Anthony
Marquez, Abby
Cregg, Jim
Liu, Yang
Milin, Anthony
Chen, Anqi
Ziv, Tamar Bar https://orcid.org/0009-0008-1751-8507
Parsons, Dylan
Knox, John E.
Klomp, Jennifer E.
Roth, Jennifer https://orcid.org/0000-0002-5117-5586
Rees, Matthew https://orcid.org/0000-0002-2987-7581
Ronan, Melissa https://orcid.org/0000-0003-4269-1404
Cuevas-Navarro, Antonio https://orcid.org/0000-0001-6208-6944
Hu, Feng https://orcid.org/0000-0001-9605-7594
Lito, Piro https://orcid.org/0000-0003-2196-3503
Santamaria, David
Aguirre, Andrew J. https://orcid.org/0000-0002-0701-6203
Waters, Andrew M. https://orcid.org/0000-0002-6058-5878
Der, Channing J. https://orcid.org/0000-0002-7751-2747
Ambrogio, Chiara https://orcid.org/0000-0003-4122-701X
Wang, Zhengping
Gill, Adrian L.
Koltun, Elena S.
Smith, Jacqueline A. M. https://orcid.org/0000-0001-5028-8725
Wildes, David https://orcid.org/0009-0009-3855-7270
Singh, Mallika https://orcid.org/0009-0003-0234-1589
- License Information
-
More Information
Article History
Received: 28 June 2023
Accepted: 16 February 2024
First Online: 8 April 2024
Competing interests
: P.L. reports grants to his institution from Amgen, Mirati, Revolution Medicines, Boehringer Ingelheim and Virtec Pharmaceuticals. P.L. reports consulting fees or honoraria from Black Diamond Therapeutics, AmMax, OrbiMed, PAQ-Tx, Repare Therapeutics, Boehringer Ingelheim and Revolution Medicines, as well as membership on the Scientific Advisory Board of Frontier Medicines, Ikena, Biotheryx and PAQ-Tx (consulting fees and equity in each). A.J.A. has consulted for Anji Pharmaceuticals, Affini-T Therapeutics, Arrakis Therapeutics, AstraZeneca, Boehringer Ingelheim, Oncorus, Merck & Co., Mirati Therapeutics, Nimbus Therapeutics, Plexium, Revolution Medicines, Reactive Biosciences, Riva Therapeutics, Servier Pharmaceuticals, Syros Pharmaceuticals, T-knife Therapeutics, Third Rock Ventures, and Ventus Therapeutics. A.J.A. holds equity in Riva Therapeutics. C.J.D. has consulted or been an advisory board member for SKY Therapeutics, Deciphera Pharmaceuticals, Kestral Therapeutics, Mirati Therapeutics, Reactive Biosciences, Revere Pharmaceuticals, Revolution Medicines, SHY Therapeutics and Sanofi. C.A. has received research fees from Revolution Medicines, Aelin Therapeutics, Verastem, Roche and Boehringer Ingelheim. The other authors declare no competing interests.
